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To compare visual field outcomes of ocular hypertensive and glaucoma patients treated with 39 
Medicine-1
st




Secondary analysis of patients from Laser in Glaucoma and Ocular Hypertension (LiGHT), a 42 
multicentre randomised controlled trial. 43 
Participants and controls 44 
344 patients (588 eyes) treated with Medicine-1
st
, 344 patients (590 eyes) treated with Laser-1
st
.  45 
Methods 46 
Visual fields (VFs) were measured using standard automated perimetry and arranged in series 47 
(median length and duration: 9 VFs over 48 months). Hierarchical linear models were used to 48 
estimate pointwise VF progression rates, which were then averaged to produce a global progression 49 
estimate for each eye. Proportions of points and patients in each treatment group with fast (< -1 50 
dB/y) or moderate (< -0.5 dB/y) progression were compared using log-binomial regression.  51 
Main outcome measures 52 
Pointwise and global progression rates of total deviation (TD) and pattern deviation (PD).  53 
Results 54 
A greater proportion of eyes underwent moderate or fast TD progression in the Medicine-1
st
 group 55 
compared with the Laser-1
st
 group (26.2% vs. 16.9%; Risk Ratio, RR = 1.55 [1.23, 1.93], P < 0.001). A 56 
similar pattern was observed for pointwise rates (Medicine-1
st
 26.1% vs. Laser-1
st
 19.0%, RR = 1.37 57 
[1.33, 1.42], P < 0.001). A greater proportion of pointwise PD rates were categorised as moderate or 58 




 11.5% vs. Laser-1
st
 8.3%, RR = 1.39 [1.32, 1.46], P < 59 
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0.001).  There was no statistical difference in the proportion of eyes that underwent moderate or 60 
fast PD progression (Medicine-1
st
 9.9% vs. Laser-1
st
 7.1%, RR = 1.39 [0.95, 2.03], P = 0.0928). 61 
Conclusion 62 
A slightly larger proportion of ocular hypertensive and glaucoma patients treated with Medicine-1
st
 63 
underwent rapid VF progression compared with those treated with Laser-1
st




Glaucoma is a progressive optic neuropathy, that left untreated can lead to loss of vision. Glaucoma 66 
can have significant implications for patients and is associated with worse vision related quality of 67 
life
1–4
. Assessing visual function, typically done by visual field (VF) examination, is vital for clinical 68 
management, especially for assessing the effectiveness of treatment in controlling the disease. VF 69 
progression will usually drive treatment intensity, as lowering intra-ocular pressure (IOP) is the only 70 
currently available treatment to slow the progression of glaucoma
5
.  71 
Thus far, IOP lowering eye drops have been used as a 1
st
-line treatment for glaucoma and ocular 72 
hypertension (OHT), but a recent report from the Laser in Glaucoma and Ocular Hypertension 73 
(LiGHT) trial showed that selective laser trabeculoplasty (SLT), an outpatient laser procedure for the 74 
reduction of IOP,  provides better clinical effectiveness and lower treatment intensity among newly 75 
diagnosed glaucoma and OHT patients compared to IOP lowering eye drops, and comparable health 76 
related quality of life, whilst also being cost-effective 
6
.  77 
Although the IOP lowering efficacy of SLT has been extensively compared to that of eye drops
7–11
 78 
and despite a substantial body of research into VF progression in glaucomatous patients, little 79 
evidence exists comparing SLT and IOP lowering eye drops in terms of VF outcomes. This study aims 80 
to compare VF progression between patients who received SLT to those who received IOP lowering 81 
eye drops, as a 1
st
-line treatment for glaucoma and OHT in the LiGHT trial.  82 
Methods 83 
Analysis cohort 84 
Details of the LiGHT trial design and baseline characteristics are described elsewhere
12,13
. Briefly, the 85 
LiGHT trial is a multi-centre, randomised controlled trial comparing IOP lowering eye drops to SLT. A 86 
total of 718 newly diagnosed, previously untreated OHT or open angle glaucoma (OAG) patients 87 
were randomised to one of two treatment pathways. Patients in the Medicine-1
st
 group received 88 
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topical IOP lowering eye drops to reduce IOP, whereas patients in the Laser-1
st
 group received SLT 89 
(followed by medication if required as the trial progressed). Subsequent treatment decisions 90 
surrounding treatment escalations, repeated SLT or trabeculectomy were conducted according to 91 
the study protocol with the aid of a computerised decision algorithm to avoid bias in clinical decision 92 
making. The decision support algorithm used in the LiGHT trial has been described in detail 93 
previously 
12,14
. Patients were treated to eye-specific IOP targets that were determined according to 94 
the computer algorithm. Recruitment lasted two years and ended in October 2014. Primary 95 
outcomes were reported at three years and additional funding allowed the trial to extend for a 96 
further three years.  97 
At each study visit, visual fields (VFs) were measured using the Humphrey Field Analyzer (HFA) with 98 
Swedish interactive threshold algorithm standard 24-2 programme (Carl Zeiss Meditec, Dublin, CA, 99 
USA). VF measurements were used primarily as an input (along with IOP and optic disc imaging 100 
measurements) into decision support software (DSS), which generated eye-specific treatment 101 
recommendations at each study visit. The secondary analysis reported here used VFs extracted from 102 
the DSS database on 13
th
 December 2018, as the trial approached the six-year mark. We constructed 103 
a longitudinal series of VFs for each study eye and these formed the basis for all analyses. A total of 104 
11,823 VFs were extracted from the database. Of these, we excluded 86 VFs with false positive rates 105 
> 14% as potentially unreliable, and 56 eyes with very short series (< 5 VFs) as these contained little 106 
information from which to estimate progression. Following these exclusions there remained 11,563 107 
VFs, approximately equally distributed between treatment groups. A total of 1178 eyes from 688 108 
patients (95.8% of those randomised) were included in this analysis; treatment groups had similar 109 
patient baseline characteristics both to each other and to previously reported analyses
6,13
 (Table 1). 110 
Median follow-up time (Medicine-1
st
 47 months, Laser-1
st
 49 months) and VF series length 111 
(Medicine-1
st
 5630 VFs, 9 VFs per eye; Laser-1
st
 5933 VFs, 10 VFs per eye) were similar across 112 
treatment groups.  113 
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Statistical analysis 114 
We compared VF outcomes between groups by constructing hierarchical linear models describing 115 
change in VF measures over time using the visual field data described above. A trend based method 116 
of comparison was chosen because it is potentially more sensitive than event based methods such as 117 
Guided Progression Analysis (GPA) for detecting progression 
15,16
, especially where the number of 118 
events is expected to be small as in these early cases. We examined change at each of the 52 119 
measured locations (excluding the blind spot) in each VF series, specifying a random effects 120 
structure nesting locations within eyes, within individuals
17
. This accounted for variation in response 121 
among locations, due to eye level variation and correlation between eyes within individuals, 122 
respectively, whilst pooling information across the entire cohort to produce the most accurate 123 
estimates. Fixed effects terms represented baseline values (equivalent to y-axis intercept [dB]) and 124 
rate of change per year (slope; dB/year) in each treatment group, enabling us to simultaneously 125 
evaluate (using the slope by group interaction term) the statistical evidence for a difference in 126 
progression rates between groups and to estimate effect size (i.e. difference in slopes)
16,18
.  127 
Two outcome variables were modelled. Total deviation (TD) is the difference of the measured 128 
sensitivity at each location from that expected for a patient of that age with no pathology. Pattern 129 
deviation (PD) is the TD value at each location adjusted for generalised depression of sensitivity 130 
across the VF
19
. Both PD and TD values were extracted from the HFA. Generalised depression and 131 
changes in TD may be caused by several non-glaucomatous conditions including cataract, whereas 132 
PD is designed to highlight the more localised VF changes found in glaucoma. However, glaucoma 133 
almost always has a diffuse component which is ignored by PD, so it is a less sensitive measure than 134 
TD and is prone to underestimation of glaucomatous damage than TD
20
. Models were fitted in R 135 
version 3.5 (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). 136 
Alongside pointwise estimates, global estimates of TD and PD progression for each study eye were 137 
extracted from the models. For each eye, the estimated rate at each location was extracted; the 138 
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mean of these pointwise rates was calculated to give the global estimate for that eye. Pointwise 139 
estimates enable better detection of spatially localised changes, whereas global estimates are useful 140 
for describing diffuse changes in sensitivity.  141 
To assess the clinical importance of differences between treatment groups, we categorised 142 
estimated progression rates of each location and eye into one of six categories (fast progression: -1 > 143 
slope dB/y, moderate progression: -1 <= slope < -0.5 dB/y, slow progression: -0.5 <= slope < 0 dB/y, 144 
slow improvement: 0 <= slope < 0.5 dB/y, moderate improvement: 0.5 <= slope < 1 dB/y, fast 145 
improvement: slope >= 1 dB/y. Category boundaries in the progression end (i.e. slope < 0) of the rate 146 
distribution were based on those previously reported in studies of glaucoma progression in clinical 147 
populations
21,22
. A symmetrical set of boundaries were applied to the improvement end of the 148 
distribution as a measure of variability. A tendency towards faster progression and also faster 149 
improvement in one treatment group (i.e. a fatter tailed distribution) would indicate greater 150 
variability in rates rather than a shift towards faster progression. We used log-binomial (relative risk) 151 
regression to compare the proportion of locations and eyes in each group undergoing fast or 152 
moderate progression, representing patients at the greatest risk of vision loss. These models were 153 
non-hierarchical, with treatment group as the predictor and the outcome being a binary variable 154 
indicating whether the estimated rates (from the hierarchical model) were above or below -0.5 dB/y. 155 
At the other end of the rate distribution, the proportions of locations and eyes undergoing fast or 156 
moderate improvement were compared in a similar manner.  157 
We conducted a sensitivity analysis to further investigate the influence of cataract, refitting our 158 
models to exclude eyes that underwent cataract removal. Similarly, eyes that underwent 159 
trabeculectomy may have experienced a step increase in sensitivity after surgery. We censored VF 160 
series for these eyes at time of surgery and refitted the models.   161 
The study adhered to the tenets of the Declaration of Helsinki. Ethical approval was obtained from 162 
local boards at each participating centre. All patients provided written informed consent before 163 
8 
 





Total deviation  167 




 groups 168 
over time (mean and 95%CI: Medicine-1
st
 = -0.25 dB/y [-0.31, -0.19]; SLT = -0.19 dB/y [-0.25, -0.13]). 169 
There was little evidence for a difference in mean rates of progression between groups (slope by 170 
group interaction term, t = 1.41, P = 0.157) but the distribution of estimated progression rates did 171 
vary by group. Distributions of both pointwise and global estimates were more strongly left skewed 172 
in the Medicine-1
st
 group than in the Laser-1
st
 group (Figure 1, global estimates), indicating that 173 
greater proportions of locations and eyes in the Medicine-1
st
 group showed evidence of more rapid 174 
progression (Table 2).  175 
One in four eyes underwent moderate or fast progression in the Medicine-1
st
 group compared with 176 
approximately one in six eyes in the Laser-1
st
 group (Risk Ratio, RR = 1.55 [1.23, 1.93], P < 0.001). 177 
Similarly, a greater proportion of locations was categorised as having moderate or fast progression 178 
in the Medicine-1
st
 group (RR = 1.37 [1.33, 1.42], P < 0.001). There was no evidence for a difference 179 
between treatment groups in the proportion of eyes that underwent moderate or fast improvement 180 
(RR 1.29 [0.83, 2.04], P = 0.266). A greater proportion of locations was categorised as having 181 
moderate or fast improvement in the Medicine-1
st
 group (RR = 1.31 [1.24, 1.39], P < 0.001). 182 
Following exclusion of eyes that underwent cataract removal, the differences between treatment 183 
groups were attenuated: eyes that underwent moderate or fast progression (RR = 1.43 [1.11, 1.83], 184 
P = 0.005); locations (RR = 1.25 [1.21, 1.29], P < 0.001). Censoring VF series at trabeculectomy had 185 
almost no influence on estimated differences between treatment groups (RRs not shown). 186 
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Pattern deviation 187 
The distribution of progression estimates was similar for pattern deviation but estimated rates were 188 
lower and differences between treatment groups were less pronounced than for total deviation. 189 




 groups 190 
over time (mean and 95%CI: Medicine-1
st
 = -0.12 dB/y [-0.16, -0.09]; Laser-1
st
 = -0.09 dB/y [-0.13, -191 
0.06]). There was no evidence for a difference in mean rates of progression between groups (t = 192 
1.19, P = 0.236) but both pointwise and global estimates were more strongly left skewed in the 193 
Medicine-1
st
 group than in the Laser-1
st
 group (Figure 2). 194 
There was no evidence for a statistical difference between treatment groups in the proportion of 195 
eyes that underwent moderate or fast progression (Table 3, RR = 1.39 [0.95, 2.03], P = 0.0928). A 196 
greater proportion of locations was categorised as having moderate or fast progression in the 197 
Medicine-1
st
 group (Table 3, RR = 1.39 [1.32, 1.46], P < 0.001). There was no evidence for a 198 
difference between treatment groups in the proportion of eyes that underwent moderate or fast 199 
improvement (RR 1.86 [0.75, 4.64], P = 0.181). A greater proportion of locations were categorised as 200 
having moderate or fast improvement in the Medicine-1
st
 group (RR = 1.37 [1.24, 1.51], P < 0.001). 201 
Following exclusion of eyes that underwent cataract removal, the differences between treatment 202 
groups were attenuated: eyes that underwent moderate or fast progression (RR = 1.18 [0.78, 1.77], 203 
P = 0.436); locations (RR = 1.29 [1.22, 1.35], P < 0.001). Censoring VF series at trabeculectomy had 204 
almost no influence on estimated differences between treatment groups (RRs not shown). 205 
Baseline sensitivity, IOP and progression rates 206 
Eyes that underwent fast progression or improvement had lower average sensitivity at baseline than 207 
those with intermediate progression or improvement rates (Figure 3). Similarly, eyes that underwent 208 
fast progression or improvement had slightly lower IOP targets set at baseline than those with 209 
10 
 
intermediate rates (Figure 4). There was no evidence that the distributions of baseline sensitivity or 210 
IOP targets differed between treatment groups (Table 1). 211 
Discussion  212 
This study reports on the VF progression differences between glaucoma/OHT patients treated with 213 
Medicine-1
st
 and patients treated with Laser-1
st
 in the LiGHT trial. Using TD values, we estimated 214 
that one in four eyes had moderate or fast VF progression in the Medicine-1
st
 group whereas in the 215 
Laser-1
st
 group this value was about one in six. The difference between groups was less pronounced, 216 
with no statistical evidence for a difference, when using PD values. The proportion of pointwise rates 217 
that were moderate or fast was slightly greater in the Medicine-1
st
 group using both PD and TD. 218 
These differences were not reflected at the upper ends of the rate distributions for either eyes or 219 
locations, indicating that our findings were not the result of greater variability in one or other 220 
treatment group.  221 
The results of this study suggest that treating patients with Laser-1
st
 may delay VF progression in 222 
comparison to Medicine-1
st
. IOP control with eye drops may rely upon patient concordance with 223 
treatment; indeed IOP lowering drops have been reportedly available to patients only 69% of the 224 
time, whilst concordance may range between 76-86% with even lower figures reported for more 225 
complex instillation regimes
23–25
. Although self-reported concordance in the LiGHT trial has been 226 
high
14
, the possibility of poor concordance having a significant adverse effect on disease control 227 
cannot be ruled out as actual dose monitoring was not carried out. However, patients in clinical trials 228 
are reported to have higher rates of concordance than those in routine care
26
. Thus the true 229 
magnitude and clinical importance of the slowing of VF progression in the Laser-1
st
 group may be 230 
much greater. SLT has also been proposed to provide better diurnal IOP stability, as a result of a 231 
continuous effect on the trabecular meshwork
27–30
. This is in contrast to the episodic (and sometimes 232 
erratic) administration of medication that may allow greater diurnal fluctuation in IOP, and in turn 233 
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faster disease progression. Even with exact concordance with instillation regimes, there are likely to 234 
be long gaps between doses overnight, during which IOP may rise.  235 
We observed differences in VF progression between treatment groups despite the fact that both 236 
groups were treated to similar IOP targets. This indicates that monitoring of IOP reduction alone 237 
(usually measured during office hours and so potentially unrepresentative of diurnal pressure 238 
variation) may be insufficient to predict functional changes indicative of progression. This suggests 239 
that clinical trials of new glaucoma treatments should include both IOP and VF related outcomes. 240 
Greater differences were observed for TD, hinting that non-glaucomatous changes may have also 241 
contributed towards differences between groups. Changes in TD may be caused by a number of non-242 
glaucomatous conditions, such as cataract. Were there higher rates of cataract in the Medicine-1
st
 243 
group it could partially explain the tendency towards faster TD progression. During the period 244 
covered by this analysis, cataracts were removed from 10.9% of eyes in the Medicine-1
st
 group and 245 
7.1% of eyes in the Laser-1
st
 group. Assuming that cataracts not yet requiring surgery follow this 246 
distribution, generalised depression of sensitivity due to lens opacity have contributed towards the 247 
differences in TD rate between the two treatment groups. This is consistent with the higher rates of 248 
cataract after topical medical treatment of glaucoma previously reported by landmark glaucoma 249 
studies
31–34
 and itself may contribute to a significant clinical advantage of a Laser-1
st
 compared to a 250 
Medicine-1
st
 protocol. Our sensitivity analysis showed that differences between treatment groups 251 
were narrowed when eyes that underwent cataract removals were excluded. PD models were as 252 
strongly influenced by the exclusions as TD models. For example, following the exclusions there was 253 
no statistical evidence for a difference in the proportion of eyes undergoing fast or moderate PD 254 
progression (there remained strong evidence for a difference in the proportion of locations with 255 
moderate or fast progression). This may indicate that as well as having lower sensitivity than TD
20
, 256 
PD may not be immune to the influence of cataract. Alternatively, the similar responses of TD and 257 
PD following exclusions may indicate that cataract was not driving the between group differences. 258 
Instead, cataract formation may be associated with faster glaucoma progression (with oxidative 259 
12 
 
stress a potential biological basis for the association) and by excluding cataract removal eyes much 260 
of the glaucoma signal may have been excluded also. Considering that we still found clinically 261 
relevant differences between treatment groups following exclusion of eyes from which cataracts 262 
were removed, and recognising the limitations of both TD and PD, we conclude that greater 263 
incidence of both cataract-related and glaucomatous progression in the Medicine-1
st
 group is likely 264 
to have contributed towards the observed differences between treatment groups. 265 
To our knowledge this is the first study to robustly compare VF outcomes between IOP lowering 266 
drops and SLT, as previous research has focused on IOP lowering alone as a surrogate for disease 267 
control. In the absence of a universally accepted, standardised classification of rates of visual field 268 
progression we have adopted that used by Chauhan et al.
21
: fast progressors as <-1dB/year (-269 
1dB/year is approximately ten times faster than age related decay). Although statistical methods 270 
differ among studies, our estimates of global TD progression are broadly comparable with MD rates 271 
in clinical glaucoma populations, which report median progression rates ranging from -0.62dB/year 272 
to -0.05dB/year)
21,35,36




 we reported the 273 
proportion of eyes with moderate or fast progression, combining these categories to ensure 274 
reasonable data support for each outcome. These figures are not directly comparable with the 275 
number of VF progressions reported in the recent paper on the primary outcomes of LiGHT
6
, where 276 
progression was detected using GPA. The proportions reported here are larger, possibly because 277 
trend based methods are more sensitive for detecting progression than event based methods such 278 
as GPA
15
, especially given the relatively high upper threshold of the moderate/fast classification (-279 
0.5dB/year). Also, this analysis covers a longer follow-up period, extending beyond the 36-month 280 
point reported previously and so a larger proportion of eyes would be expected to show evidence of 281 
VF progression in our study. Despite these methodological differences, both analyses report higher 282 
risks of VF progression in the Medicine-1
st
 group, that may be related to the higher rates of disease 283 
deterioration previously reported
6
.  284 
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This VF analysis is more detailed than those previously reported for LiGHT 
6,14,37
 in that pointwise 285 
rates were modelled and then averaged to produce global rate estimates, retaining more 286 
information than if global VF measures such as MD or Pattern Standard Deviation (PSD) had been 287 
used. Furthermore, we considered the overall shapes of the progression rate distributions rather 288 
than using the mean of each distribution as the single point of comparison. We show that 289 
differences between treatment groups were manifest only towards the more rapidly progressing 290 
end of the rate distribution. If we had concentrated solely on mean TD and PD we would have found 291 
no differences between treatment groups, consistent with the MD and PSD results reported at 36-292 
months
14
.   293 
The data derived for this study were drawn from a carefully conducted, randomised controlled trial.   294 
Patients were monitored according to routine clinical care; the trial used eye specific IOP targets 295 
which were objectively defined and adjusted by a computerised decision algorithm to avoid bias
12
. 296 
Similarly, to avoid bias in clinical decision making, treatment escalation decisions were initiated by 297 
the computerised decision algorithm, which followed a robust protocol developed according to 298 
international guidelines by the EGS, American Academy of Ophthalmology Preferred Practice Pattern 299 
and the and the South-East Asia Glaucoma Interest Group
38–40
. The decision support algorithm used 300 
in the LiGHT trial has been described in detail before 
12,14
. The success of this strategy is highlighted 301 
by the well matched distributions of baseline damage and IOP targets between treatment groups 302 
(Table 1, Figures 3 and 4). As a result, any differences in VF progression between treatment groups 303 
reflect genuine change, in the presence of identical IOP control practices between the two groups. 304 
Patients treated with Laser-1
st
 exhibited slower VF progression, as shown in this study, in addition to 305 
better IOP control, less intense medical and surgical treatment and lower rates of disease 306 
deterioration
6
.   307 
The data presented here support the use of SLT as a first line treatment for glaucoma and OHT as 308 
suggested by the previously reported improved clinical outcomes, lower treatment intensity and 309 
14 
 
cost-savings for the NHS. With slower VF deterioration SLT may delay or completely avert the need 310 
for more intense medical and surgical intervention in a significant proportion of patients.  311 
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Figure legends 426 
Figure 1. Distribution of estimated global total deviation progression rates by treatment group. 427 
Histogram with median and 10
th
 percentiles indicated. Curved line represents a smoothed density 428 
estimate to the histogram. 429 
Figure 2. Distribution of estimated global pattern deviation progression rates by treatment group. 430 
Histogram with median and 10
th
 percentiles indicated. Curved line represents a smoothed density 431 
estimate to the histogram. 432 
Figure 3. Distribution of mean deviation (MD) at baseline by estimated total deviation progression 433 
rates.  434 
Figure 4. Distribution of target IOP at baseline by estimated total deviation progression rates. 435 
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Table 1. Distribution of cohort characteristics by treatment group. Values given are frequencies 
unless otherwise marked. 
 Medicine-1st Laser-1st 
Patients 344 344 
Male 180 (52.3%) 193 (56.1%) 
Female 164 (47.7%) 151 (43.9%) 
Age in years, mean (SD) 62.9 (11.6) 63.4 (12.0) 
OAG 271 (78.8%) 266 (77.3%) 
OHT 73 (21.2%) 78 (22.7%) 
Eyes 588 590 
Bilateral cases 245 (71.2%) 249 (72.4%) 
Follow up duration in months, median (IQR) 47 (39, 54) 49 (42, 56) 
Visual fields 5630 5933 
Visual fields per eye, median (IQR) 9 (8, 11) 10 (8, 12) 
Interval between fields in days, median (IQR) 135 (83, 189) 140 (94, 189) 
Visual field mean deviation at baseline in dB, median (IQR) -2.0 (-4.5, -0.5) -2.2 (-4.4, -0.6) 
IOP target at baseline in mmHg, median (IQR) 18 (16,  21) 18 (16, 21) 




Table 2. Distribution of estimated total deviation progression rates by treatment group. 
 Locations  Eyes  
Progression rate Medicine-1st Laser-1st Medicine-1st Laser-1st 
Fast (-1 > slope dB/y) 10.2% (3115) 6.0% (1848) 9.5% (56) 5.4% (32) 
Moderate (-1 <= slope < -0.5 dB/y) 15.9% (4864) 13.0% (3980) 16.7% (98) 11.5% (68) 
Slow (-0.5 <= slope < 0 dB/y) 40.3% (12336) 43.4% (13311) 41.5% (244) 48.1% (284) 
Slow improvement  
(0 <= slope < 0.5 dB/y) 
25.7% (7863) 31.6% (9705) 25.5% (150) 29.7% (175) 
Moderate improvement  
(0.5 <= slope < 1 dB/y) 
5.9% (1798) 4.7% (1442) 5.1% (30) 4.1% (24) 




Table 3. Distribution of estimated pattern deviation progression rates by treatment group. 
 Locations  Eyes  
Progression rate Medicine-1st Laser-1st Medicine-1st Laser-1st 
Fast (-1 > slope dB/y) 4.6% (1403) 3.2% (967) 3.4% (20) 1.7% (10) 
Moderate (-1 <= slope < -0.5 dB/y) 6.9% (2103) 5.1% (1565) 6.5% (38) 5.4% (32) 
Slow (-0.5 <= slope < 0 dB/y) 46.6% (14234) 48.9% (14990) 51.7% (304) 55.6% (328) 
Slow improvement  
(0 <= slope < 0.5 dB/y) 
38.9% (11900) 40.6% (12471) 36.2% (213) 36.1% (213) 
Moderate improvement  
(0.5 <= slope < 1 dB/y) 
2.6% (805) 1.8% (557) 2.2% (13) 1.0% (6) 
Fast improvement (slope >= 1 dB/y) 0.4% (131) 0.4% (130) - (0) 0.2% (1) 
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